News
DENVER — Early data for a new vaccine for pancreatic cancer is generating some hope among patients, researchers and doctors.
New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.
Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.
Black and Hispanic people are more likely to be diagnosed with pancreatic cancer and more likely to die from it. Now, one drug may help fix this.
Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in treatment for cancers, rare disease and more.
In fact, only 10 per cent of patients are diagnosed in time for life-saving surgery. But a potential vaccine is now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback